Before too long, it'll be the AGM and everyone can ask all the questions they want. I suspect the company is simply interested in the bigger and more profitable markets available through "off-the-shelf" products, than what any autologous based therapy will ever allow. MSB is geared toward becoming a "large" bio-pharma, not a specialist "personalised medicine" provider, our CEO has made that clear.
They MAY have once [perhaps seriously] toyed with the idea of "personalised" but realised their current generation MPC based treatments are much more suited toward "mass market" medicine.
I see no major negatives with MSB and simply encourage them to keep programs advancing.
dme - [again] we need to keep moving, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |